 Abstract metabolic-associated fatty liver disease, MAFLD, is becoming more prevalent due to lifestyle changes and dietary habits. Gut microbes play a role in the development of MAFLD by altering the composition of the gut microbiome. This study examined the gut microbiome of MAFLD patients and healthy controls, finding that certain bacteria were enriched in the MAFLD patients. Additionally, the abundance of certain bacteria was correlated with the severity of liver damage. These findings suggest that the gut microbiome could serve as a biomarker for MAFLD and could potentially be used to develop new treatments for the condition. This article was offered by Chaoyang, Jionwoshu, Saminshu, and others.